| 词条 | Lomitapide |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 444364270 | IUPAC_name = N-(2,2,2-Trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9H-fluoren-9-carboxamde | image = Lomitapide_skeletal.svg | tradename = Juxtapid (US), Lojuxta (EU) | pregnancy_AU = | pregnancy_US = X | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Oral (capsules) | licence_US = Lomitapide | licence_EU = yes | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | IUPHAR_ligand = 7439 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 182431-12-5 | CAS_supplemental = {{CAS|202914-84-9}} (mesilate) | ATC_prefix = C10 | ATC_suffix = AX12 | ATC_supplemental = | PubChem = 9853053 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 82KUB0583F | ChEBI_Ref = {{ebicite|changed|EBI}} | ChEBI = 72297 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D09637 | synonyms = AEGR-773, BMS-201038 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 8028764 | chemical_formula = | C=39 | H=37 | F=6 | N=3 | O=2 | molecular_weight = 693.719 g/mol | smiles = FC(F)(F)c5ccc(cc5)-c1ccccc1C(=O)NC4CCN(CC4)CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c6ccccc26 | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49) | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = MBBCVAKAJPKAKM-UHFFFAOYSA-N }}Lomitapide (INN, marketed as Juxtapid in the US and as Lojuxta in the EU) is a drug used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals.[1] It has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate.[2][3] The US Food and Drug Administration (FDA) approved lomitapide on 21 December 2012, as an orphan drug to reduce LDL cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH).[4] On 31 May 2013 the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion with a unanimous vote recommending a marketing authorization for lomitapide.[5] On 31 July 2013 the European Commission approved lomitapide as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with HoFH. Mechanism of actionLomitapide inhibits the microsomal triglyceride transfer protein (MTP or MTTP) which is necessary for very low-density lipoprotein (VLDL) assembly and secretion in the liver.[1][6] On 24 December 2012, drug manufacturer Aegerion announced they had been approved by the FDA to as "an adjunct to a low-fat diet and other lipid-lowering treatments...in patients with homozygous familial hypercholesterolemia (HoFH)."[7][8] Side effectsIn a Phase III study, lomitapide led to elevated aminotransferase levels and fat accumulation in the liver.[6] References1. ^1 {{cite journal| author = H. Spreitzer| date = 12 March 2007| title = Neue Wirkstoffe – BMS-201038| journal = Österreichische Apothekerzeitung| issue = 6/2007| pages = 268| language = German }} 2. ^{{cite journal|last=Samaha|first=Frederick F|author2=James McKenney |author3=LeAnne T Bloedon |author4=William J Sasiela |author5=Daniel J Rader |year=2008|title=Impact of the MTP-Inhibitor, AEGR-733, as Monotherapy and in Combination with Ezetimibe on Lipid Subfractions as Measured by NMR Spectroscopy|journal=Circulation|volume=118|pages=469–71|pmid=18663098|issue=5|doi=10.1161/CIRCULATIONAHA.108.792689}} 3. ^Aegerion Pharmaceuticals, Inc. Announces AEGR-733 Phase II Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile {{webarchive|url=https://web.archive.org/web/20120229092512/http://www.pr-inside.com/aegerion-pharmaceuticals-inc-announces-aegr-r904473.htm |date=2012-02-29 }} 4. ^"FDA approves new orphan drug for rare cholesterol disorder" 5. ^European Medicines Agency: Lojuxta 6. ^1 {{Cite journal | last1 = Cuchel | first1 = M. | last2 = Bloedon | first2 = L. T. | last3 = Szapary | first3 = P. O. | last4 = Kolansky | first4 = D. M. | last5 = Wolfe | first5 = M. L. | last6 = Sarkis | first6 = A. | last7 = Millar | first7 = J. S. | last8 = Ikewaki | first8 = K. | last9 = Siegelman | first9 = E. S. | last10 = Gregg | first10 = R. E. | last11 = Rader | first11 = D. J. | title = Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia | journal = New England Journal of Medicine | volume = 356 | pages = 148–156 | year = 2007 | doi = 10.1056/NEJMoa061189| pmid=17215532 | issue=2}} 7. ^{{cite web|title=FDA Approves Juxtapid for Homozygous Familial Hypercholesteolemia|url=http://www.dailyrx.com/juxtapid-reduces-cholesterol-patients-homozygous-familial-hypercholesterolemia|date=26 December 2012}} 8. ^{{cite press release| url = http://ir.aegerion.com/releasedetail.cfm?ReleaseID=728650| title = FDA Approves Aegerion Pharmaceuticals' Juxtapid (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH)| publisher = Aegerion Pharmaceuticals| date = 24 December 2012}} External links
7 : Benzamides|Biphenyls|Fluorenes|Hypolipidemic agents|Organofluorides|Piperidines|Trifluoromethyl compounds |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。